Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG06466 in Focal Epilepsy with RNS
NCT05081518Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-1431 in focal epilepsy (2 arms), sponsored by Lundbeck. Primary endpoint: Number of Long Episodes (Electrocorticographic [ECoG] Seizures). Started Sep 2021; status: terminated.
02
Drugs
ABX-1431
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT05081518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081518.